Bendamustine was synthesized to combine a purine and amino acid antagonist with an alkylating nitrogen mustard group (bifunctional alkylating agent). The major advantage of Bendamustine, compared to chlorambucil, is its favored water solubility. On the other hand, Bendamustine has been proven to be safe. It is indicated as single-agent therapy or in combination with other antineoplastic drugs for the treatment of the following malignancies: Hodgkin's disease (stages II-IV), non-Hodgkin's lymphoma (NHL), plasmocytoma; chronic lymphocytic leukaemia (CLL), and breast cancer. In March 25th, 2008, INNOPHARMAX has signed a license agreement with SymBio Pharmaceuticals Ltd. for the sublicense rights to Bendamustine HCl in Taiwan.